The University of Medicine and Pharmacy Iuliu Haţieganu
Academic institution
Cluj-Napoca
Romania
Iuliu Hatieganu is one of eastern europe's leading medical centers, and is home to more than 1,100 teachers and researchers
Iuliu Hațieganu University of Medicine and Pharmacy in Cluj-Napoca, Romania, is the continuation of the Faculty of Medicine and Pharmacy which was founded in 1919, as a part of the Superior Dacia University. The university has over 6,000 national and international students, 2,400 resident physicians, as well as over 1,100 teachers and researchers.
Iuliu Haţieganu University of Medicine and Pharmacy is dedicated to achieving excellence in scientific research. Our researchers have won an increasing number of European and national competitions for research funding. The number of articles published in reputed international science journals is increasing rapidly each year.
In the last couple of years, UMF has rocketed into second place for the number of medical and pharmaceutical research projects receiving funding from national and international organizations. In 2010, our University won grants to the total amount of 73.872.646, 39 RON ( 15 mil euros).On account of the dynamic activity of our young researchers and the value of their work, several prestigious European universities are now offering joint doctorates with UMF. The results of these studies are published in acclaimed international journals. At UMF, the emphasis is placed on fundamental and clinical research conducted in clearly defined areas, in line with the latest research topics. The setting up of European and international partnerships is strongly encouraged. In 2010, we established the Research Centre for Functional Genomics, Biomedicine and Translational Medicine.
The University has entered a series of research partnership agreements with reputed European universities and encourages joint doctorates, in order to produce highly qualified researchers. After extensive evaluation, several research and excellence clusters have been identified. The University’s ongoing priorities in regard to research include the development of highly trained and qualified researchers, the establishment of state-of-the-art research infrastructure, the orientation of fundamental research towards clinical applications and the publishing of research results to increase institutional visibility.
UMF Iuliu Hatieganu is a founder member of WIN due to its important capacity of developing functional genomics studies and clinical trials in cancer in Eastern Europe.
Iuliu Haţieganu University of Medicine and Pharmacy is dedicated to achieving excellence in scientific research. Our researchers have won an increasing number of European and national competitions for research funding. The number of articles published in reputed international science journals is increasing rapidly each year.
In the last couple of years, UMF has rocketed into second place for the number of medical and pharmaceutical research projects receiving funding from national and international organizations. In 2010, our University won grants to the total amount of 73.872.646, 39 RON ( 15 mil euros).On account of the dynamic activity of our young researchers and the value of their work, several prestigious European universities are now offering joint doctorates with UMF. The results of these studies are published in acclaimed international journals. At UMF, the emphasis is placed on fundamental and clinical research conducted in clearly defined areas, in line with the latest research topics. The setting up of European and international partnerships is strongly encouraged. In 2010, we established the Research Centre for Functional Genomics, Biomedicine and Translational Medicine.
The University has entered a series of research partnership agreements with reputed European universities and encourages joint doctorates, in order to produce highly qualified researchers. After extensive evaluation, several research and excellence clusters have been identified. The University’s ongoing priorities in regard to research include the development of highly trained and qualified researchers, the establishment of state-of-the-art research infrastructure, the orientation of fundamental research towards clinical applications and the publishing of research results to increase institutional visibility.
UMF Iuliu Hatieganu is a founder member of WIN due to its important capacity of developing functional genomics studies and clinical trials in cancer in Eastern Europe.
